Onduo and Orpyx to Offer Expanded Market Solutions for Virtual Type 2 Diabetes Care
Boston, MA, United States, June 10, 2019 – Onduo has partnered with Orpyx Medical Technologies Inc. (Orpyx) to expand market solutions offered to interested healthcare partners this year. Clients of Onduo’s integrated hardware and software solution will be able to expand the program to include access to Orpyx foot ulcer sensors for their identified diabetes population. Orpyx clients will also be able to include access to Onduo’s Virtual Diabetes Clinic to their population. Together, Orpyx and Onduo are jointly committed to keeping people with diabetes from foot ulcer complications and reducing long-term healthcare costs for those patients and the partners covering their medical care.
Onduo’s Virtual Diabetes Clinic provides personalized care to those diagnosed with type 2 diabetes. Onduo leverages behavioral change best practices such as coaching and blood monitoring tools that integrate with its app. Members can also access to a higher level of care, including deeper monitoring with continuous glucose monitors (CGMs), training with certified diabetes educators, and telemedicine support from endocrinologists via its virtual clinic.
Today, 25 percent of people with diabetes develop foot ulcers over their lifetime, and one in five of those people experience complications that lead to amputation.1 In the U.S. alone, almost one million diabetes-related foot ulcers are treated each year, costing upwards of $30,000 USD per ulcer with complications that can result in amputation.2
“Through our dynamic foot sensor technology, we help patients with diabetes stay mobile and reduce the risk of foot complications, such as ulcers, that often lead to limb loss,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc. “We are excited to partner with Onduo to provide our foot sensor technology to their member community so they can continue to stay active and live their best lives.”
“There are a lot of diabetes management companies that do lifestyle and coaching. At Onduo, we do the same but our clinic is particularly focused on bringing deep clinical interventions that can help those who need more,” said Dr. Josh Riff, CEO of Onduo. “One of the top complications – and cost drivers – of living with type 2 diabetes is foot ulcers. This joint offering with Orpyx give us both an advantage to better target and address the interventional needs for those who need it.”
Onduo and Orpyx share a vision of a world where everyone has access to the medical care and resources they need, no matter where they live or what health conditions they face. For more information, visit www.onduo.com/orpyx.
Onduo is a virtual diabetes program that provides the tools, coaching and access to specialty doctors that you need to take control of your diabetes and learn what works for you. Founded in 2016 as a joint venture between Verily and Sanofi, Onduo is dedicated to bringing the most up to date care to people living with diabetes – anytime, anywhere. Learn more at www.onduo.com.
About Orpyx Medical Technologies Inc.
Founded in 2010, Orpyx Medical Technologies empowers people with diabetes to maintain mobility. Orpyx’s core product line, the SurroSense® intelligent insole systems, help manage and prevent diabetic foot ulcers and limb loss through FDA cleared, advanced foot sensor technology and analytics. Orpyx’s technology is used by researchers to access clinical-grade plantar pressure measurement data for health and human performance applications. Orpyx is focused on collaborating with stakeholders around the world to achieve a healthcare future that is prevention focused and sustainable in cost. Learn more at www.orpyx.com.
For more information, please contact:
+1 774 217-1330
Marketing Manager, Orpyx Medical Technologies Inc.
+1 403 460 0216 ext. 501
1 Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–28.
2 Ragnarson Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis. 2004;39 Suppl 2:S132–S139.